Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Brookline starts MiRagen Therapeutics at buy; PT $6

Brookline Capital Markets initiated coverage of MiRagen Therapeutics (NASDAQ:MGEN) with a “buy” rating and 12-to-18 month price target of $6. The stock closed at $1.02 on July 20. MiRagen is working in hematologic...

July 21, 2020

Markets

BTIG starts Akouos at buy; PT $35

BTIG initiated coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $35 price target. The stock closed at $21.12 on July 20. Akouos is focused on the development of highly specific genetic medicines for hearing loss...

July 21, 2020

Markets

AGP starts EyeGate Pharma at buy; PT $9.50

Alliance Global Partners launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy” rating and price target of $9.50, representing a price-to-sales multiple of eight times based on 2022 revenue estimates...

July 21, 2020

Markets

Piper Sandler starts Zynex at OW; PT $30

Piper Sandler launched coverage of Zynex (NASDAQ:ZYXI) with an “overweight” rating and $30 price target. The stock closed at $21.42 on July 17. Zynex sells the only three-in-one, at home, chronic pain management product...

July 20, 2020

Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020

Markets

BTIG slashes NextCure PT to $27 from $61

BTIG more than halved the price target for NextCure (NASDAQ:NXTC) to $27 from $61 after the company announced that its NC318 immunoncology antibody would not be moving forward into stage 2 of the Simon-2-stage trial in...

July 14, 2020

Markets

SVB Leerink cuts Benefytt Technologies to MP; PT up to $31 from $27.50

SVB Leerink downgraded Benefytt Technologies (NASDAQ:BFYT) to “market perform” from “outperform” but raised its price target to $31 from $27.50 after Madison Dearborn Partners agreed to acquire Benefytt for $31 a share...

July 14, 2020

Markets

BTIG cuts Gritstone Oncology PT to $17 from $31

BTIG reduced its price target for Gritstone Oncology (NASDAQ:GRTS) to $17 from $31, citing interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen...

July 14, 2020

Markets

BTIG ups Vapotherm PT to $53 from $32

BTIG raised its price target for Vapotherm (NASDAQ:VAPO) to $53 from $32, citing a higher compound annual growth rate for revenue after a proprietary survey of U.S. hospitals that purchased the company’s Precision Flow...

July 13, 2020

Developments Markets

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

The Mayo Clinic has just been listed as a new TULSA-PRO site, representing the first sale of the system to a teaching hospital by the technology’s developer, Profound Medical Profound Medical (TSX:PRN; NASDAQ:PROF)...

July 9, 2020

Markets

Maxim ups Biolife Solutions PT to $26 from $18

Maxim Group raised its price target for Biolife Solutions (NASDAQ:BLFS) to $26 from $18, citing a strengthening balance sheet, with management continuing to execute on its growth strategy. The stock closed at $17.59 on...

July 8, 2020

Markets

SVB Leerink cuts Radius Health to MP; PT to $17 from $34

SVB Leerink downgraded Radius Health (NASDAQ:RDUS) to “market perform” from “outperform” and halved its price target to $17 from $34, citing the company’s pipeline outlook. The stock closed at $14.06 on July 7. “We...

July 8, 2020

Markets

Maxim starts TFF Pharma at buy; PT $12

Maxim Group launched coverage of TFF Pharmaceuticals (NASDAQ:TFFP) with a “buy” rating and $12 price target. The stock closed at $6.22 on July 7. The company is using its thin film freezing (TFF) platform to develop two...

July 8, 2020

Markets

Chardan starts NGM Biopharmaceuticals at buy; PT $40

Chardan Capital Markets launched coverage of NGM Biopharmaceuticals (NASDAQ:NGM) with a “buy” rating and $40 price target. The stock closed at $19.01 on July 6. “We anticipate that NGM’s aldafermin is likely to...

July 7, 2020

Markets

AGP starts Organigram at buy; PT $4

Alliance Global Partners initiated coverage of Organigram Holdings (TSX:OGI) with a “buy” rating and price target of $4 (Canadian). The stock closed at $2.11 on July 6. “We view Organigram’s low-cost indoor [cannabis]...

July 7, 2020

Markets

Chardan starts Akero Therapeutics at buy; PT $79

Chardan Capital Markets launched coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and $79 price target. The stock closed at $34.96 on July 6. “We expect that Akero’s lead asset, efruxifermin, has...

July 7, 2020

Markets

BTIG starts Venus Concept at buy; PT $7

BTIG initiated coverage of Venus Concept (NASDAQ:VERO) with a “buy” rating and $7 price target. The stock closed at $3.52 on June 2. “It is not an easy time to be an aesthetics device company amidst the COVID-19...

July 6, 2020

Markets

SVB Leerink starts AdaptHealth at OP; PT $21

SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...

July 1, 2020

Markets

CohBar added to Russell 2000 index; raises $4.4-million in ATM offering

CohBar (NASDAQ:CWBR) was added to the small-cap Russell 2000 index during its latest reconstitution. The company also sold common stock through its existing at-the-market (ATM) offering, with net proceeds of about $4.4...

June 30, 2020

Markets

SVB Leerink starts Applied Molecular at OP; PT $32

SVB Leerink initiated coverage of Applied Molecular Transport (NASDAQ:AMTI) with an “outperform” rating and $32 price target. The stock closed at $25.80 on June 29. “We believe Applied’s emerging translocation...

June 30, 2020

Markets

HCW starts Merus NV at buy; PT $23

H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...

June 26, 2020

Markets

BTIG ups Mersana Therapeutics PT to $32 from $21

BTIG raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $32 from $21, saying the company’s STING agonist antibody-drug conjugates look compelling on the evolving immunoncology landscape. The stock closed...

June 24, 2020

Subscribe